<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20241013081801&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20241013081801&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sun, 13 Oct 2024 12:18:02 +0000</lastbuilddate>
<pubDate>Sat, 12 Oct 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Structural basis of respiratory complex adaptation to cold temperatures</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39395414/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241013081801&amp;v=2.18.0.post9+e462414
      <description>In response to cold, mammals activate brown fat for respiratory-dependent thermogenesis reliant on the electron transport chain. Yet, the structural basis of respiratory complex adaptation upon cold exposure remains elusive. Herein, we combined thermoregulatory physiology and cryoelectron microscopy (cryo-EM) to study endogenous respiratory supercomplexes from mice exposed to different temperatures. A cold-induced conformation of CI:III(2) (termed type 2) supercomplex was identified with a ∼25°...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 3:S0092-8674(24)01087-0. doi: 10.1016/j.cell.2024.09.029. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In response to cold, mammals activate brown fat for respiratory-dependent thermogenesis reliant on the electron transport chain. Yet, the structural basis of respiratory complex adaptation upon cold exposure remains elusive. Herein, we combined thermoregulatory physiology and cryoelectron microscopy (cryo-EM) to study endogenous respiratory supercomplexes from mice exposed to different temperatures. A cold-induced conformation of CI:III<sub>2</sub> (termed type 2) supercomplex was identified with a ∼25° rotation of CIII<sub>2</sub> around its inter-dimer axis, shortening inter-complex Q exchange space, and exhibiting catalytic states that favor electron transfer. Large-scale supercomplex simulations in mitochondrial membranes reveal how lipid-protein arrangements stabilize type 2 complexes to enhance catalytic activity. Together, our cryo-EM studies, multiscale simulations, and biochemical analyses unveil the thermoregulatory mechanisms and dynamics of increased respiratory capacity in brown fat at the structural and energetic level.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39395414/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241013081801&v=2.18.0.post9+e462414">39395414</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.029>10.1016/j.cell.2024.09.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39395414</guid>
<pubDate>Sat, 12 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Young-Cheul Shin</dc:creator>
<dc:creator>Pedro Latorre-Muro</dc:creator>
<dc:creator>Amina Djurabekova</dc:creator>
<dc:creator>Oleksii Zdorevskyi</dc:creator>
<dc:creator>Christopher F Bennett</dc:creator>
<dc:creator>Nils Burger</dc:creator>
<dc:creator>Kangkang Song</dc:creator>
<dc:creator>Chen Xu</dc:creator>
<dc:creator>Joao A Paulo</dc:creator>
<dc:creator>Steven P Gygi</dc:creator>
<dc:creator>Vivek Sharma</dc:creator>
<dc:creator>Maofu Liao</dc:creator>
<dc:creator>Pere Puigserver</dc:creator>
<dc:date>2024-10-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Structural basis of respiratory complex adaptation to cold temperatures</dc:title>
<dc:identifier>pmid:39395414</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.029</dc:identifier>
</item>
<item>
<title>Genome integrity sensing by the broad-spectrum Hachiman antiphage defense complex</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39395413/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241013081801&amp;v=2.18.0.post9+e462414
      <description>Hachiman is a broad-spectrum antiphage defense system of unknown function. We show here that Hachiman is a heterodimeric nuclease-helicase complex, HamAB. HamA, previously a protein of unknown function, is the effector nuclease. HamB is the sensor helicase. HamB constrains HamA activity during surveillance of intact double-stranded DNA (dsDNA). When the HamAB complex detects DNA damage, HamB helicase activity activates HamA, unleashing nuclease activity. Hachiman activation degrades all DNA in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 3:S0092-8674(24)01068-7. doi: 10.1016/j.cell.2024.09.020. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Hachiman is a broad-spectrum antiphage defense system of unknown function. We show here that Hachiman is a heterodimeric nuclease-helicase complex, HamAB. HamA, previously a protein of unknown function, is the effector nuclease. HamB is the sensor helicase. HamB constrains HamA activity during surveillance of intact double-stranded DNA (dsDNA). When the HamAB complex detects DNA damage, HamB helicase activity activates HamA, unleashing nuclease activity. Hachiman activation degrades all DNA in the cell, creating "phantom" cells devoid of both phage and host DNA. We demonstrate Hachiman activation in the absence of phage by treatment with DNA-damaging agents, suggesting that Hachiman responds to aberrant DNA states. Phylogenetic similarities between the Hachiman helicase and enzymes from eukaryotes and archaea suggest deep functional symmetries with other important helicases across domains of life.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39395413/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241013081801&v=2.18.0.post9+e462414">39395413</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.020>10.1016/j.cell.2024.09.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39395413</guid>
<pubDate>Sat, 12 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Owen T Tuck</dc:creator>
<dc:creator>Benjamin A Adler</dc:creator>
<dc:creator>Emily G Armbruster</dc:creator>
<dc:creator>Arushi Lahiri</dc:creator>
<dc:creator>Jason J Hu</dc:creator>
<dc:creator>Julia Zhou</dc:creator>
<dc:creator>Joe Pogliano</dc:creator>
<dc:creator>Jennifer A Doudna</dc:creator>
<dc:date>2024-10-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Genome integrity sensing by the broad-spectrum Hachiman antiphage defense complex</dc:title>
<dc:identifier>pmid:39395413</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.020</dc:identifier>
</item>
<item>
<title>Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39394525/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241013081801&amp;v=2.18.0.post9+e462414
      <description>Dilated cardiomyopathy (DCM) is a complex disease with multiple causes and various pathogenic mechanisms. Despite improvements in the prognosis of patients with DCM in the past decade, this condition remains a leading cause of heart failure and premature death. Conventional treatment for DCM is based on the foundational therapies for heart failure with reduced ejection fraction. However, increasingly, attention is being directed towards individualized treatments and precision medicine. The...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Oct 11. doi: 10.1038/s41569-024-01074-2. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Dilated cardiomyopathy (DCM) is a complex disease with multiple causes and various pathogenic mechanisms. Despite improvements in the prognosis of patients with DCM in the past decade, this condition remains a leading cause of heart failure and premature death. Conventional treatment for DCM is based on the foundational therapies for heart failure with reduced ejection fraction. However, increasingly, attention is being directed towards individualized treatments and precision medicine. The ability to confirm genetic causality is gradually being complemented by an increased understanding of genotype-phenotype correlations. Non-genetic factors also influence the onset of DCM, and growing evidence links genetic background with concomitant non-genetic triggers or precipitating factors, increasing the extreme complexity of the pathophysiology of DCM. This Review covers the spectrum of pathophysiological mechanisms in DCM, from monogenic causes to the coexistence of genetic abnormalities and triggering environmental factors (the 'two-hit' hypothesis). The roles of common genetic variants in the general population and of gene modifiers in disease onset and progression are also discussed. Finally, areas for future research are highlighted, particularly novel therapies, such as small molecules, RNA and gene therapy, and measures for the prevention of arrhythmic death.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39394525/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241013081801&v=2.18.0.post9+e462414">39394525</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01074-2>10.1038/s41569-024-01074-2</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39394525</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Marta Gigli</dc:creator>
<dc:creator>Davide Stolfo</dc:creator>
<dc:creator>Marco Merlo</dc:creator>
<dc:creator>Gianfranco Sinagra</dc:creator>
<dc:creator>Matthew R G Taylor</dc:creator>
<dc:creator>Luisa Mestroni</dc:creator>
<dc:date>2024-10-11</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine</dc:title>
<dc:identifier>pmid:39394525</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01074-2</dc:identifier>
</item>
<item>
<title>Clinical and subclinical acute brain injury caused by invasive cardiovascular procedures</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39394524/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241013081801&amp;v=2.18.0.post9+e462414
      <description>Over the past 50 years, the number and invasiveness of percutaneous cardiovascular procedures globally have increased substantially. However, cardiovascular interventions are inherently associated with a risk of acute brain injury, both periprocedurally and postprocedurally, which impairs medical outcomes and increases health-care costs. Current international clinical guidelines generally do not cover the area of acute brain injury related to cardiovascular invasive procedures. In this...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Oct 11. doi: 10.1038/s41569-024-01076-0. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Over the past 50 years, the number and invasiveness of percutaneous cardiovascular procedures globally have increased substantially. However, cardiovascular interventions are inherently associated with a risk of acute brain injury, both periprocedurally and postprocedurally, which impairs medical outcomes and increases health-care costs. Current international clinical guidelines generally do not cover the area of acute brain injury related to cardiovascular invasive procedures. In this international Consensus Statement, we compile the available knowledge (including data on prevalence, pathophysiology, risk factors, clinical presentation and management) to formulate consensus recommendations on the prevention, diagnosis and treatment of acute brain injury caused by cardiovascular interventions. We also identify knowledge gaps and possible future directions in clinical research into acute brain injury related to cardiovascular interventions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39394524/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241013081801&v=2.18.0.post9+e462414">39394524</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01076-0>10.1038/s41569-024-01076-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39394524</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Radosław Lenarczyk</dc:creator>
<dc:creator>Marco Proietti</dc:creator>
<dc:creator>Jan F Scheitz</dc:creator>
<dc:creator>Dipen Shah</dc:creator>
<dc:creator>Eberhard Siebert</dc:creator>
<dc:creator>Diana A Gorog</dc:creator>
<dc:creator>Jacek Kowalczyk</dc:creator>
<dc:creator>Nikolaos Bonaros</dc:creator>
<dc:creator>George Ntaios</dc:creator>
<dc:creator>Wolfram Doehner</dc:creator>
<dc:creator>Nicolas M Van Mieghem</dc:creator>
<dc:creator>Sandor Nardai</dc:creator>
<dc:creator>Jan Kovac</dc:creator>
<dc:creator>Roland Fiszer</dc:creator>
<dc:creator>Roberto Lorusso</dc:creator>
<dc:creator>Eliano Navarese</dc:creator>
<dc:creator>Sergio Castrejón</dc:creator>
<dc:creator>Andrea Rubboli</dc:creator>
<dc:creator>José Miguel Rivera-Caravaca</dc:creator>
<dc:creator>Alaide Chieffo</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:date>2024-10-11</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Clinical and subclinical acute brain injury caused by invasive cardiovascular procedures</dc:title>
<dc:identifier>pmid:39394524</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01076-0</dc:identifier>
</item>
<item>
<title>Correction to: Great debate: myocardial infarction after cardiac surgery must be redefined</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39392465/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241013081801&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 11:ehae734. doi: 10.1093/eurheartj/ehae734. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39392465/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241013081801&v=2.18.0.post9+e462414">39392465</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae734>10.1093/eurheartj/ehae734</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39392465</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:date>2024-10-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Great debate: myocardial infarction after cardiac surgery must be redefined</dc:title>
<dc:identifier>pmid:39392465</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae734</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: FINEARTS-HF supports the role of aldosterone antagonism in the management of heart failure with mildly reduced or preserved ejection fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39392246/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241013081801&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 11:ehae679. doi: 10.1093/eurheartj/ehae679. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39392246/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241013081801&v=2.18.0.post9+e462414">39392246</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae679>10.1093/eurheartj/ehae679</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39392246</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Massimo Volpe</dc:creator>
<dc:creator>Leonarda Galiuto</dc:creator>
<dc:date>2024-10-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: FINEARTS-HF supports the role of aldosterone antagonism in the management of heart failure with mildly reduced or preserved ejection fraction</dc:title>
<dc:identifier>pmid:39392246</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae679</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: is MATTERHORN a game changer for secondary mitral regurgitation? Still climbing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39392244/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241013081801&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 11:ehae650. doi: 10.1093/eurheartj/ehae650. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39392244/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241013081801&v=2.18.0.post9+e462414">39392244</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae650>10.1093/eurheartj/ehae650</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39392244</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:date>2024-10-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: is MATTERHORN a game changer for secondary mitral regurgitation? Still climbing</dc:title>
<dc:identifier>pmid:39392244</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae650</dc:identifier>
</item>
<item>
<title>Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39392008/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241013081801&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: ANGPTL3/8 potently inhibited GPIHBP1-LPL enzymatic activity, consistent with its positive association with serum lipids. However, ANGPTL3/8, LDL-C, and triglyceride levels were not associated with cardiovascular death in the LURIC and getABI cohorts. In contrast, concentrations of ANGPTL4/8 and particularly CD-ANGPTL4 were positively associated with inflammation, the prevalence of diabetes, and cardiovascular mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 11. doi: 10.1161/CIRCULATIONAHA.124.069272. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: ANGPTL3/4/8 (angiopoietin-like proteins 3, 4, and 8) are important regulators of LPL (lipoprotein lipase). ANGPTL8 forms complexes with ANGPTL3 and ANGPTL4. ANGPTL4/8 complex formation converts ANGPTL4 from a furin substrate to a plasmin substrate, and both cleavages generate similar C-terminal domain-containing (CD)-ANGPTL4 fragments. Whereas several studies have investigated associations of free ANGPTL proteins with cardiovascular risk, there are no data describing associations of the complexes and CD-ANGPTL4 with outcomes or describing the effects of the complexes on LPL bound to GPIHBP1 (glycosylphosphatidylinositol HDL-binding protein 1).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Recombinant protein assays were used to study ANGPTL protein and complex effects on GPIHBP1-LPL activity. ANGPTL3/8, ANGPTL3, ANGPTL4/8, and CD-ANGPTL4 were measured with dedicated immunoassays in 2394 LURIC (Ludwigshafen Risk and Cardiovascular Health) study participants undergoing coronary angiography and 6188 getABI study (German Epidemiological Trial on Ankle Brachial Index) participants undergoing ankle brachial index measurement. There was a follow-up for cardiovascular death with a median (interquartile range) duration of 9.80 (8.75-10.40) years in the LURIC study and 7.06 (7.00-7.14) years in the getABI study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: ANGPTL3/8 potently inhibited GPIHBP1-LPL activity and showed positive associations with LDL-C (low-density lipoprotein cholesterol) and triglycerides (both <i>P</i>&lt;0.001). However, in neither study did ANGPTL3/8 correlate with cardiovascular death. Free ANGPTL3 was positively associated with cardiovascular death in the getABI study but not the LURIC study. ANGPTL4/8 and especially CD-ANGPTL4 were positively associated with the prevalence of diabetes, CRP (C-reactive protein; all <i>P</i>&lt;0.001), and cardiovascular death in both studies. In the LURIC and getABI studies, respective hazard ratios for cardiovascular mortality comparing the third with the first ANGPTL4/8 tertile were 1.47 (1.15-1.88) and 1.68 (1.25-2.27) when adjusted for sex, age, body mass index, and diabetes. For CD-ANGPTL4, these hazard ratios were 2.44 (1.86-3.20) and 2.76 (2.00-3.82).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: ANGPTL3/8 potently inhibited GPIHBP1-LPL enzymatic activity, consistent with its positive association with serum lipids. However, ANGPTL3/8, LDL-C, and triglyceride levels were not associated with cardiovascular death in the LURIC and getABI cohorts. In contrast, concentrations of ANGPTL4/8 and particularly CD-ANGPTL4 were positively associated with inflammation, the prevalence of diabetes, and cardiovascular mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39392008/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241013081801&v=2.18.0.post9+e462414">39392008</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069272>10.1161/CIRCULATIONAHA.124.069272</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39392008</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Günther Silbernagel</dc:creator>
<dc:creator>Yan Q Chen</dc:creator>
<dc:creator>Hongxia Li</dc:creator>
<dc:creator>Deven Lemen</dc:creator>
<dc:creator>Yi Wen</dc:creator>
<dc:creator>Eugene Y Zhen</dc:creator>
<dc:creator>Martin Rief</dc:creator>
<dc:creator>Marcus E Kleber</dc:creator>
<dc:creator>Graciela Delgado</dc:creator>
<dc:creator>Mark A Sarzynski</dc:creator>
<dc:creator>Yue-Wei Qian</dc:creator>
<dc:creator>Boerge Schmidt</dc:creator>
<dc:creator>Raimund Erbel</dc:creator>
<dc:creator>Ulrike Trampisch</dc:creator>
<dc:creator>Angela P Moissl</dc:creator>
<dc:creator>Henrik Rudolf</dc:creator>
<dc:creator>Heribert Schunkert</dc:creator>
<dc:creator>Andreas Stang</dc:creator>
<dc:creator>Winfried März</dc:creator>
<dc:creator>Hans J Trampisch</dc:creator>
<dc:creator>Hubert Scharnagl</dc:creator>
<dc:creator>Robert J Konrad</dc:creator>
<dc:date>2024-10-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality</dc:title>
<dc:identifier>pmid:39392008</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069272</dc:identifier>
</item>
<item>
<title>YAP Overcomes Mechanical Barriers to Induce Mitotic Rounding and Adult Cardiomyocyte Division</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39392007/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241013081801&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our data reveal that YAP5SA overcomes the mechanically constrained myocardial microenvironment to induce mitotic rounding with cardiomyocyte division, thus providing new insights into the in vivo mechanisms that maintain cell cycle quiescence in adult mammals.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 11. doi: 10.1161/CIRCULATIONAHA.123.066004. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Many specialized cells in adult organs acquire a state of cell cycle arrest and quiescence through unknown mechanisms. Our limited understanding of mammalian cell cycle arrest is derived primarily from cell culture models. Adult mammalian cardiomyocytes, a classic example of cell cycle arrested cells, exit the cell cycle postnatally and remain in an arrested state for the life of the organism. Cardiomyocytes can be induced to re-enter the cell cycle by YAP5SA, an active form of the Hippo signaling pathway effector YAP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We performed clonal analyses to determine the cell kinetics of YAP5SA cardiomyocytes. We also performed single-cell RNA sequencing, marker gene analysis, and functional studies to examine how YAP5SA cardiomyocytes progress through the cell cycle.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We discovered that YAP5SA-expressing cardiomyocytes divided efficiently, with >;20% of YAP5SA cardiomyocyte clones containing ≥2 cardiomyocytes. YAP5SA cardiomyocytes re-entered cell cycle at the G1/S transition and had an S phase lasting ≈48 hours. Sarcomere disassembly is required for cardiomyocyte progression from S to G2 phase and the induction of mitotic rounding. Although oscillatory Cdk expression was induced in YAP5SA cardiomyocytes, these cells inefficiently progressed through G2 phase. This is improved by inhibiting P21 function, implicating checkpoint activity as an additional barrier to YAP5SA-induced cardiomyocyte division.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our data reveal that YAP5SA overcomes the mechanically constrained myocardial microenvironment to induce mitotic rounding with cardiomyocyte division, thus providing new insights into the in vivo mechanisms that maintain cell cycle quiescence in adult mammals.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39392007/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241013081801&v=2.18.0.post9+e462414">39392007</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066004>10.1161/CIRCULATIONAHA.123.066004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39392007</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Yuka Morikawa</dc:creator>
<dc:creator>Jong H Kim</dc:creator>
<dc:creator>Rich Gang Li</dc:creator>
<dc:creator>Lin Liu</dc:creator>
<dc:creator>Shijie Liu</dc:creator>
<dc:creator>Vaibhav Deshmukh</dc:creator>
<dc:creator>Matthew C Hill</dc:creator>
<dc:creator>James F Martin</dc:creator>
<dc:date>2024-10-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>YAP Overcomes Mechanical Barriers to Induce Mitotic Rounding and Adult Cardiomyocyte Division</dc:title>
<dc:identifier>pmid:39392007</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066004</dc:identifier>
</item>
<item>
<title>A Rare Noncoding Enhancer Variant in &lt;em>;SCN5A&lt;/em>; Contributes to the High Prevalence of Brugada Syndrome in Thailand</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39391988/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241013081801&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This is the first example of a functionally validated rare noncoding variant at the SCN5A locus and highlights how genome sequencing in understudied populations can identify novel disease mechanisms. The variant partly explains the increased prevalence of BrS in this region and enables the identification of at-risk variant carriers to reduce the burden of sudden cardiac death in Thailand.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 11. doi: 10.1161/CIRCULATIONAHA.124.069041. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Brugada syndrome (BrS) is a cardiac arrhythmia disorder that causes sudden death in young adults. Rare genetic variants in the <i>SCN5A</i> gene encoding the Na<sub>v</sub>1.5 sodium channel and common noncoding variants at this locus are robustly associated with the condition. BrS is particularly prevalent in Southeast Asia but the underlying ancestry-specific factors remain largely unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Genome sequencing of BrS probands and population-matched controls from Thailand was performed to identify rare noncoding variants at the <i>SCN5A-SCN10A</i> locus that were enriched in patients with BrS. A likely causal variant was prioritized by computational methods and introduced into human induced pluripotent stem cell (hiPSC) lines using CRISPR-Cas9. The effect of the variant on <i>SCN5A</i> expression and Na<sub>v</sub>1.5 sodium channel current was then assessed in hiPSC-derived cardiomyocytes (hiPSC-CMs).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A rare noncoding variant in an <i>SCN5A</i> intronic enhancer region was highly enriched in patients with BrS (detected in 3.9% of cases with a case-control odds ratio of 45.2). The variant affects a nucleotide conserved across all mammalian species and predicted to disrupt a Mef2 transcription factor binding site. Heterozygous introduction of the enhancer variant in hiPSC-CMs caused significantly reduced <i>SCN5A</i> expression from the variant-containing allele and a 30% reduction in Na<sub>v</sub>1.5-mediated sodium current density compared with isogenic controls, confirming its pathogenicity. Patients with the variant had severe phenotypes, with 89% experiencing cardiac arrest.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This is the first example of a functionally validated rare noncoding variant at the <i>SCN5A</i> locus and highlights how genome sequencing in understudied populations can identify novel disease mechanisms. The variant partly explains the increased prevalence of BrS in this region and enables the identification of at-risk variant carriers to reduce the burden of sudden cardiac death in Thailand.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39391988/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241013081801&v=2.18.0.post9+e462414">39391988</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069041>10.1161/CIRCULATIONAHA.124.069041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39391988</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Roddy Walsh</dc:creator>
<dc:creator>John Mauleekoonphairoj</dc:creator>
<dc:creator>Isabella Mengarelli</dc:creator>
<dc:creator>Fernanda M Bosada</dc:creator>
<dc:creator>Arie O Verkerk</dc:creator>
<dc:creator>Karel van Duijvenboden</dc:creator>
<dc:creator>Yong Poovorawan</dc:creator>
<dc:creator>Wanwarang Wongcharoen</dc:creator>
<dc:creator>Boosamas Sutjaporn</dc:creator>
<dc:creator>Pharawee Wandee</dc:creator>
<dc:creator>Nitinan Chimparlee</dc:creator>
<dc:creator>Ronpichai Chokesuwattanaskul</dc:creator>
<dc:creator>Kornkiat Vongpaisarnsin</dc:creator>
<dc:creator>Piyawan Dangkao</dc:creator>
<dc:creator>Cheng-I Wu</dc:creator>
<dc:creator>Rafik Tadros</dc:creator>
<dc:creator>Ahmad S Amin</dc:creator>
<dc:creator>Krystien V V Lieve</dc:creator>
<dc:creator>Pieter G Postema</dc:creator>
<dc:creator>Maarten Kooyman</dc:creator>
<dc:creator>Leander Beekman</dc:creator>
<dc:creator>Dujdao Sahasatas</dc:creator>
<dc:creator>Montawatt Amnueypol</dc:creator>
<dc:creator>Rungroj Krittayaphong</dc:creator>
<dc:creator>Somchai Prechawat</dc:creator>
<dc:creator>Alisara Anannab</dc:creator>
<dc:creator>Pattarapong Makarawate</dc:creator>
<dc:creator>Tachapong Ngarmukos</dc:creator>
<dc:creator>Keerapa Phusanti</dc:creator>
<dc:creator>Gumpanart Veerakul</dc:creator>
<dc:creator>Zoya Kingsbury</dc:creator>
<dc:creator>Taksina Newington</dc:creator>
<dc:creator>Uma Maheswari</dc:creator>
<dc:creator>Mark T Ross</dc:creator>
<dc:creator>Andrew Grace</dc:creator>
<dc:creator>Pier D Lambiase</dc:creator>
<dc:creator>Elijah R Behr</dc:creator>
<dc:creator>Jean-Jacques Schott</dc:creator>
<dc:creator>Richard Redon</dc:creator>
<dc:creator>Julien Barc</dc:creator>
<dc:creator>Vincent M Christoffels</dc:creator>
<dc:creator>Arthur A M Wilde</dc:creator>
<dc:creator>Koonlawee Nademanee</dc:creator>
<dc:creator>Connie R Bezzina</dc:creator>
<dc:creator>Apichai Khongphatthanayothin</dc:creator>
<dc:date>2024-10-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Rare Noncoding Enhancer Variant in &lt;em>;SCN5A&lt;/em>; Contributes to the High Prevalence of Brugada Syndrome in Thailand</dc:title>
<dc:identifier>pmid:39391988</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069041</dc:identifier>
</item>
<item>
<title>Using artificial intelligence to document the hidden RNA virosphere</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39389057/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241013081801&amp;v=2.18.0.post9+e462414
      <description>Current metagenomic tools can fail to identify highly divergent RNA viruses. We developed a deep learning algorithm, termed LucaProt, to discover highly divergent RNA-dependent RNA polymerase (RdRP) sequences in 10,487 metatranscriptomes generated from diverse global ecosystems. LucaProt integrates both sequence and predicted structural information, enabling the accurate detection of RdRP sequences. Using this approach, we identified 161,979 potential RNA virus species and 180 RNA virus...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 3:S0092-8674(24)01085-7. doi: 10.1016/j.cell.2024.09.027. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Current metagenomic tools can fail to identify highly divergent RNA viruses. We developed a deep learning algorithm, termed LucaProt, to discover highly divergent RNA-dependent RNA polymerase (RdRP) sequences in 10,487 metatranscriptomes generated from diverse global ecosystems. LucaProt integrates both sequence and predicted structural information, enabling the accurate detection of RdRP sequences. Using this approach, we identified 161,979 potential RNA virus species and 180 RNA virus supergroups, including many previously poorly studied groups, as well as RNA virus genomes of exceptional length (up to 47,250 nucleotides) and genomic complexity. A subset of these novel RNA viruses was confirmed by RT-PCR and RNA/DNA sequencing. Newly discovered RNA viruses were present in diverse environments, including air, hot springs, and hydrothermal vents, with virus diversity and abundance varying substantially among ecosystems. This study advances virus discovery, highlights the scale of the virosphere, and provides computational tools to better document the global RNA virome.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39389057/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241013081801&v=2.18.0.post9+e462414">39389057</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.027>10.1016/j.cell.2024.09.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39389057</guid>
<pubDate>Thu, 10 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Xin Hou</dc:creator>
<dc:creator>Yong He</dc:creator>
<dc:creator>Pan Fang</dc:creator>
<dc:creator>Shi-Qiang Mei</dc:creator>
<dc:creator>Zan Xu</dc:creator>
<dc:creator>Wei-Chen Wu</dc:creator>
<dc:creator>Jun-Hua Tian</dc:creator>
<dc:creator>Shun Zhang</dc:creator>
<dc:creator>Zhen-Yu Zeng</dc:creator>
<dc:creator>Qin-Yu Gou</dc:creator>
<dc:creator>Gen-Yang Xin</dc:creator>
<dc:creator>Shi-Jia Le</dc:creator>
<dc:creator>Yin-Yue Xia</dc:creator>
<dc:creator>Yu-Lan Zhou</dc:creator>
<dc:creator>Feng-Ming Hui</dc:creator>
<dc:creator>Yuan-Fei Pan</dc:creator>
<dc:creator>John-Sebastian Eden</dc:creator>
<dc:creator>Zhao-Hui Yang</dc:creator>
<dc:creator>Chong Han</dc:creator>
<dc:creator>Yue-Long Shu</dc:creator>
<dc:creator>Deyin Guo</dc:creator>
<dc:creator>Jun Li</dc:creator>
<dc:creator>Edward C Holmes</dc:creator>
<dc:creator>Zhao-Rong Li</dc:creator>
<dc:creator>Mang Shi</dc:creator>
<dc:date>2024-10-10</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Using artificial intelligence to document the hidden RNA virosphere</dc:title>
<dc:identifier>pmid:39389057</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.027</dc:identifier>
</item>
<item>
<title>Retraction notice to: hnRNP K: An HDM2 Target and Transcriptional Coactivator of p53 in Response to DNA Damage</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39389056/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241013081801&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 9:S0092-8674(24)01156-5. doi: 10.1016/j.cell.2024.10.008. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39389056/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241013081801&v=2.18.0.post9+e462414">39389056</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.008>10.1016/j.cell.2024.10.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39389056</guid>
<pubDate>Thu, 10 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Abdeladim Moumen</dc:creator>
<dc:creator>Philip Masterson</dc:creator>
<dc:creator>Mark J O'Connor</dc:creator>
<dc:creator>Stephen P Jackson</dc:creator>
<dc:date>2024-10-10</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Retraction notice to: hnRNP K: An HDM2 Target and Transcriptional Coactivator of p53 in Response to DNA Damage</dc:title>
<dc:identifier>pmid:39389056</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.008</dc:identifier>
</item>
<item>
<title>Optimizing AHA/ACC Guidelines for the Digital Age: Guidelines in Evolution</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39388581/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241013081801&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 10. doi: 10.1161/CIR.0000000000001294. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39388581/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241013081801&v=2.18.0.post9+e462414">39388581</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001294>10.1161/CIR.0000000000001294</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39388581</guid>
<pubDate>Thu, 10 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Catherine M Otto</dc:creator>
<dc:creator>Mariell Jessup</dc:creator>
<dc:creator>Richard J Kovacs</dc:creator>
<dc:creator>Joshua A Beckman</dc:creator>
<dc:date>2024-10-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Optimizing AHA/ACC Guidelines for the Digital Age: Guidelines in Evolution</dc:title>
<dc:identifier>pmid:39388581</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001294</dc:identifier>
</item>
<item>
<title>Salt and CHIP: &lt;em>;Tet2&lt;/em>;-CH Aggravates Salt-Sensitive Hypertension in Mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39388535/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241013081801&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 11;135(9):951-953. doi: 10.1161/CIRCRESAHA.124.325364. Epub 2024 Oct 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39388535/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241013081801&v=2.18.0.post9+e462414">39388535</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325364>10.1161/CIRCRESAHA.124.325364</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39388535</guid>
<pubDate>Thu, 10 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Caitlyn Vlasschaert</dc:creator>
<dc:creator>Steven D Crowley</dc:creator>
<dc:creator>Alexander G Bick</dc:creator>
<dc:date>2024-10-10</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Salt and CHIP: &lt;em>;Tet2&lt;/em>;-CH Aggravates Salt-Sensitive Hypertension in Mice</dc:title>
<dc:identifier>pmid:39388535</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325364</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39388534/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241013081801&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 11;135(9):888-889. doi: 10.1161/RES.0000000000000696. Epub 2024 Oct 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39388534/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241013081801&v=2.18.0.post9+e462414">39388534</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000696>10.1161/RES.0000000000000696</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39388534</guid>
<pubDate>Thu, 10 Oct 2024 06:00:00 -0400</pubDate>
<dc:date>2024-10-10</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:39388534</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000696</dc:identifier>
</item>
<item>
<title>β-blockers after MI: does ABYSS confirm REDUCEd use after all?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39384949/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241013081801&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Oct 9. doi: 10.1038/s41569-024-01093-z. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39384949/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241013081801&v=2.18.0.post9+e462414">39384949</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01093-z>10.1038/s41569-024-01093-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39384949</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Robin Hofmann</dc:creator>
<dc:creator>Stefan James</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>β-blockers after MI: does ABYSS confirm REDUCEd use after all?</dc:title>
<dc:identifier>pmid:39384949</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01093-z</dc:identifier>
</item>
<item>
<title>Tribute to an Outstanding Clinician and Friend Roman DeSanctis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39384266/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241013081801&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 15;84(16):1582-1583. doi: 10.1016/j.jacc.2024.08.020.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39384266/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241013081801&v=2.18.0.post9+e462414">39384266</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.020>10.1016/j.jacc.2024.08.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39384266</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Valentin Fuster</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Tribute to an Outstanding Clinician and Friend Roman DeSanctis</dc:title>
<dc:identifier>pmid:39384266</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.020</dc:identifier>
</item>
<item>
<title>Opioid Overdose in Patients With Concomitant Use of Tramadol and Clopidogrel vs Alternative Antiplatelet Agents</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39384265/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241013081801&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 15;84(16):1578-1581. doi: 10.1016/j.jacc.2024.07.036.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39384265/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241013081801&v=2.18.0.post9+e462414">39384265</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.036>10.1016/j.jacc.2024.07.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39384265</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Sungho Bea</dc:creator>
<dc:creator>Krista F Huybrechts</dc:creator>
<dc:creator>Heba H Edrees</dc:creator>
<dc:creator>C Andrew Basham</dc:creator>
<dc:creator>Seanna M Vine</dc:creator>
<dc:creator>Robert J Glynn</dc:creator>
<dc:creator>Brian T Bateman</dc:creator>
<dc:creator>Katsiaryna Bykov</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Opioid Overdose in Patients With Concomitant Use of Tramadol and Clopidogrel vs Alternative Antiplatelet Agents</dc:title>
<dc:identifier>pmid:39384265</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.036</dc:identifier>
</item>
<item>
<title>International Clinical Practice Guideline Recommendations for Acute Pulmonary Embolism: Harmony, Dissonance, and Silence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39384264/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241013081801&amp;v=2.18.0.post9+e462414
      <description>Despite abundant clinical innovation and burgeoning scientific investigation, pulmonary embolism (PE) has continued to pose a diagnostic and management challenge worldwide. Aging populations, patients living with a mounting number of chronic medical conditions, particularly cancer, and increasingly prevalent health care disparities herald a growing burden of PE. In the meantime, navigating expanding strategies for immediate and long-term anticoagulation, as well as advanced therapies, including...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 15;84(16):1561-1577. doi: 10.1016/j.jacc.2024.07.044.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Despite abundant clinical innovation and burgeoning scientific investigation, pulmonary embolism (PE) has continued to pose a diagnostic and management challenge worldwide. Aging populations, patients living with a mounting number of chronic medical conditions, particularly cancer, and increasingly prevalent health care disparities herald a growing burden of PE. In the meantime, navigating expanding strategies for immediate and long-term anticoagulation, as well as advanced therapies, including catheter-based interventions for patients with more severe PE, has become progressively daunting. Accordingly, clinicians frequently turn to evidence-based clinical practice guidelines for diagnostic and management recommendations. However, numerous international guidelines, heterogeneity in recommendations, as well as areas of uncertainty or omission may leave the readers and clinicians without a clear management pathway. In this review of international PE guidelines, we highlight key areas of consistency, difference, and lack of recommendations (silence) with an emphasis on critical clinical and research needs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39384264/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241013081801&v=2.18.0.post9+e462414">39384264</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.044>10.1016/j.jacc.2024.07.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39384264</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Marco Zuin</dc:creator>
<dc:creator>Behnood Bikdeli</dc:creator>
<dc:creator>Jennifer Ballard-Hernandez</dc:creator>
<dc:creator>Stefano Barco</dc:creator>
<dc:creator>Elisabeth M Battinelli</dc:creator>
<dc:creator>George Giannakoulas</dc:creator>
<dc:creator>David Jimenez</dc:creator>
<dc:creator>Frederikus A Klok</dc:creator>
<dc:creator>Darsiya Krishnathasan</dc:creator>
<dc:creator>Irene M Lang</dc:creator>
<dc:creator>Lisa Moores</dc:creator>
<dc:creator>Katelyn W Sylvester</dc:creator>
<dc:creator>Jeffrey I Weitz</dc:creator>
<dc:creator>Gregory Piazza</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>International Clinical Practice Guideline Recommendations for Acute Pulmonary Embolism: Harmony, Dissonance, and Silence</dc:title>
<dc:identifier>pmid:39384264</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.044</dc:identifier>
</item>
<item>
<title>Optimizing Outcomes in ST-Segment Elevation Myocardial Infarction: Is Prolonged Infusion of Bivalirudin Part of the Solution?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39384263/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241013081801&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 15;84(16):1525-1527. doi: 10.1016/j.jacc.2024.08.049.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39384263/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241013081801&v=2.18.0.post9+e462414">39384263</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.049>10.1016/j.jacc.2024.08.049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39384263</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthew A Cavender</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Optimizing Outcomes in ST-Segment Elevation Myocardial Infarction: Is Prolonged Infusion of Bivalirudin Part of the Solution?</dc:title>
<dc:identifier>pmid:39384263</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.049</dc:identifier>
</item>
<item>
<title>Bivalirudin vs Heparin Anticoagulation in STEMI: Confirmation of the BRIGHT-4 Results</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39384262/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241013081801&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In STEMI patients undergoing primary PCI, bivalirudin with a 2- to 4-hour post-PCI high-dose infusion reduced cardiac mortality and major bleeding without an increase in ischemic events compared with heparin monotherapy with provisional GPI use, confirming the BRIGHT-4 results.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 15;84(16):1512-1524. doi: 10.1016/j.jacc.2024.07.045.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In the BRIGHT-4 (Bivalirudin With Prolonged Full-Dose Infusion During Primary PCI Versus Heparin Trial-4), anticoagulation with bivalirudin plus a 2- to 4-hour high-dose infusion after percutaneous coronary intervention (PCI) reduced all-cause mortality and bleeding without increasing reinfarction or stent thrombosis compared with heparin alone in patients with ST-segment elevation myocardial infarction (STEMI). These findings require external validation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to determine outcomes of bivalirudin vs heparin anticoagulation during PCI in STEMI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We performed an individual-patient-data meta-analysis of all large randomized trials of bivalirudin vs heparin in STEMI patients undergoing primary PCI performed before BRIGHT-4. The primary endpoint was all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Six trials randomizing 15,254 patients were included. Pooled across all regimens of bivalirudin and glycoprotein IIb/IIIa inhibitor (GPI) use, bivalirudin reduced 30-day all-cause mortality (2.5% vs 2.9%; adjusted OR: 0.78; 95% CI: 0.62-0.99), cardiac mortality (adjusted OR: 0.69; 95% CI: 0.54-0.88), and major bleeding (adjusted OR: 0.53; 95% CI: 0.44-0.64) but increased reinfarction (adjusted OR: 1.30; 95% CI: 1.02-1.65) and stent thrombosis (adjusted OR: 1.43; 95% CI: 1.05-1.93) compared with heparin. In 4 trials in which 6,244 patients were randomized to bivalirudin plus a high-dose post-PCI infusion vs heparin without planned GPI use (the BRIGHT-4 regimens), 30-day all-cause mortality occurred in 1.8% vs 2.9% of patients, respectively (adjusted OR: 0.74; 95% CI: 0.48-1.12), and bivalirudin reduced cardiac mortality (adjusted OR: 0.62; 95% CI: 0.39-0.97) and major bleeding (adjusted OR: 0.49; 95% CI: 0.35-0.70), with similar rates of reinfarction (adjusted OR: 0.89; 95% CI: 0.58-1.38) and stent thrombosis (adjusted OR: 0.80; 95% CI: 0.41-1.57).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In STEMI patients undergoing primary PCI, bivalirudin with a 2- to 4-hour post-PCI high-dose infusion reduced cardiac mortality and major bleeding without an increase in ischemic events compared with heparin monotherapy with provisional GPI use, confirming the BRIGHT-4 results.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39384262/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241013081801&v=2.18.0.post9+e462414">39384262</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.045>10.1016/j.jacc.2024.07.045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39384262</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:creator>David Erlinge</dc:creator>
<dc:creator>Yaling Han</dc:creator>
<dc:creator>Philippe Gabriel Steg</dc:creator>
<dc:creator>Rod H Stables</dc:creator>
<dc:creator>Enrico Frigoli</dc:creator>
<dc:creator>Stefan K James</dc:creator>
<dc:creator>Yi Li</dc:creator>
<dc:creator>Patrick Goldstein</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Ghazaleh Mehdipoor</dc:creator>
<dc:creator>Aaron Crowley</dc:creator>
<dc:creator>Shmuel Chen</dc:creator>
<dc:creator>Björn Redfors</dc:creator>
<dc:creator>Clayton Snyder</dc:creator>
<dc:creator>Zhipeng Zhou</dc:creator>
<dc:creator>Behnood Bikdeli</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Bivalirudin vs Heparin Anticoagulation in STEMI: Confirmation of the BRIGHT-4 Results</dc:title>
<dc:identifier>pmid:39384262</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.045</dc:identifier>
</item>





























</channel>
</rss>